Key Market Indicators
Austrian antirheumatic medicine sales are projected to dip to just over $40 million by 2026. In 2021, the country was ranked 16th with sales of $44 million. Slovakia was ahead with sales of $44.22 million, followed by Germany, Spain and Canada. Since 2015, the Austrian market has declined at an average rate of 0.8% year on year.
